Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
371.67(c) 384.16(c) 377.55(c) 398.52(c) 399.06 Last
761 560 810 180 444 917 684 490 439 969 Volume
-2.69% +3.36% -1.72% +5.55% +0.14% Change
More quotes
Financials (USD)
Sales 2018 6 458 M
EBIT 2018 2 715 M
Net income 2018 1 886 M
Finance 2018 3 549 M
Yield 2018 -
Sales 2019 7 115 M
EBIT 2019 2 948 M
Net income 2019 2 251 M
Finance 2019 5 739 M
Yield 2019 -
P/E ratio 2018 22,48
P/E ratio 2019 21,10
EV / Sales2018 5,76x
EV / Sales2019 4,92x
Capitalization 40 777 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases.It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP.The company was founded by... 
Sector
Biotechnology & Medical Research
Calendar
10/20 | 12:30pmPresentation
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
10/17REGENERON PHARMACEUTICALS : Dupixent (dupilumab) Showed Positive Topline Results..
AQ
10/16SANOFI : ICER weighing issuing advice on trial design
AQ
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/16REGENERON PHARMACEUTICALS : Dupixent® (dupilumab) Showed Positive Topline Result..
PR
10/12REGENERON PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events, Financia..
AQ
10/09REGENERON PHARMACEUTICALS : Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congres..
PR
10/08REGENERON PHARMACEUTICALS : to Report Third Quarter 2018 Financial and Operating..
PR
10/03REGENERON PHARMACEUTICALS : Fda approves libtayo as first and only treatment for..
AQ
10/01Blueprint Medicines unveils preclinical data for rare bone disease program
AQ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More news
Sector news : Bio Therapeutic Drugs
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/27Novartis strikes deal with Chinese firm to make Kymriah
RE
More sector news : Bio Therapeutic Drugs
MarketScreener Strategies on REGENERON PHARMACEUTICALS 
REGENERON PHARMACEUTICALS - 2017
A long term support level to be taken advantage of
BUY
REGENERON PHARMACEUTICALS - 2017
One can take advantage of the trading range to enter new positions
BUY
More Strategies
Latest Tweets
10/17$1.66 Billion in Sales Expected for Regeneron Pharmaceuticals Inc $REGN This .. 
10/17Largest gainers today 10/16/2018 on my Watch List were: $REGN $ANET $IBP $COH.. 
10/16$REGN still coiled on weekly
1
10/16Regeneron data won't derail Intersect ENT's Sinuva, says Leerink $REGN $XENT ..
2
10/16$AAPL $AMGN $AMZN $BIIB $BRK.B $CELG $GE $GILD $GOOGL $GS $INTC $JPM $M $MS $.. 
More tweets
Qtime:128
News from SeekingAlpha
10/17DUPIXENT : Top-Down And Bottom-Up Perspectives On The News 
10/16Regeneron's Dupixent successful in late-stage rhinosinusitis studies 
10/15Aimmune teams up with Regeneron and Sanofi in mid-stage peanut allergy study;.. 
10/15Protect Your Portfolio And Increase Returns By Focusing On Earnings Trends 
10/13STOCKS TO WATCH : Was That A Speed Bump? 
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Average target price 408 $
Spread / Average Target 2,5%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS2.18%40 777
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671
GENMAB-11.78%8 632